Why a compound being unapproved is not the same as being illegal to possess
Post #10 answers the question as asked. The question underneath it is different.
Import restrictions vary by compound and by jurisdiction: what is a controlled substance in one place is legal to purchase in another. What you can import for personal use depends on your country's rules, not on where it is sold.
Anyone with a larger sample, please post it.
Everything in post #39 holds. The case it does not cover is the one I have.
A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.
Worth one more sentence than it usually gets.
Practical answer on compound being unapproved, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict and vary by jurisdiction. Generalising from one country's rules to another's is unreliable.
The uncertainty is in the assumption, not in the calculation.
Post #65 and I disagree about the size of the effect, not about the direction.
Labelling and intended use: a compound sold as "research-use-only" does not change its pharmacology if ingested. It changes the legal status of the sale. The labelling tells you the intended use, not the actual use people make of it.
That is what I would do. It may not be what is correct.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The label does not establish whether the molecule is safe, efficacious, or toxic.
Correct me on the arithmetic if it is wrong; I would rather know.
Post #72 is right about the mechanism and I think understates the practical bit.
Two questions I would want answered before drawing anything from the compound being unapproved data above: how were the cases selected, and what happened to the ones that dropped out.
Read the full topic (79 posts)
This topic was referenced in
- Research-use-only labelling: what it means and what it does notSourcing › Regulatory · 110 replies
- Follow-up: How compounding permissions changed when supply normalisedSourcing › Regulatory · 77 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
|
+87 | 94 | 1.1k | 21d |
|
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says, since the…
|
+8 | 12 | 15k | 17h |
|
Follow-up: How compounding permissions changed when supply normalised
How compounding permissions changed when supply normalised I have a specific reason for asking rather than idle curiosity, and the context is below. I was wrong about compounding permissions in a thread last…
|
+72 | 77 | 1.5k | 1d |
|
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. I would like to know what people here actually do…
|
+76 | 82 | 52k | 11mo |
|
About the Regulatory category
Research-use-only status, compounding rules, import restrictions, and the primary documents behind them. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 49k | 4mo |
Related topics — sharing the tags FDA, MHRA, research use only
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Personal import allowances, compared — a second dataset
Personal import allowances, compared — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Personal import allowances. It is mine, it is…
|
+124 | 132 | 9.2k | 2mo |
|
Prescription requirements and telehealth models — a second dataset
On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…
|
+87 | 94 | 1.1k | 21d |
|
Payment method and the leverage it gives you, ranked
Posting this under the heading it deserves: Payment method and the leverage it gives you, ranked Everything below is what sits behind that. A payments question, with the mechanics separated from the money.…
|
+71 | 76 | 56k | 10mo |
|
A payment that went through twice: how it was resolved
A payment that went through twice: how it was resolved Writing it up because I had to work it out twice and would rather nobody else did. A payments question, with the mechanics separated from the money. What…
|
+20 | 24 | 55k | 3mo |
|
Manufacturer assistance programmes and their eligibility rules
On the subject in the title: Manufacturer assistance programmes and their eligibility rules Working notes rather than a conclusion. I have spent a fortnight trying to pin manufacturer assistance programmes…
|
+37 | 42 | 32k | 11d |